Eton Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Eton Pharmaceuticals

13/05/2025 22:02

Eton Pharmaceuticals Inc ETON.OQ reported quarterly adjusted earnings of 7 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -3 cents.  The mean expectation of three analysts for the quarter was for earnings of 5 cents per share. Wall Street expected results to range from -1 cents to 13 cents per share.

Revenue rose 116.9% to $17.28 million from a year ago; analysts expected $15.13 million.

Eton Pharmaceuticals Inc's reported EPS for the quarter was a loss of 6 cents​.

The company reported a quarterly loss of $1.57 million.

Eton Pharmaceuticals Inc shares had risen by 33.7% this quarter and gained 30.3% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 100% in the last three months.​

In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Eton Pharmaceuticals Inc is $26.00

This summary was machine generated from LSEG data May 13 at 09:02 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
0.05
0.07
Beat
Dec. 31 2024
0.00
-0.02
Missed
Sep. 30 2024
-0.01
0.03
Beat
Jun. 30 2024
-0.07
-0.12
Missed